Abstract
Phenylbutazone (Butazolidin®), one of the newer antirheumatic drugs, while providing varying degrees of symptomatic relief in various types of rheumatism, may also cause serious toxic side effects. It is most effective in acute gout, and slightly less so in rheumatoid arthritis, of both the spondylitic and peripheral types. Its use in degenerative arthritis is not indicated. Its toxic side effects include gastrointestinal upsets, edema, rash, stomatitis, purpura, hematuria, agranulocytosis and reactivation of peptic ulcer. Several fatalities have been reported. It is, however, a valuable drug if used properly. Extreme caution should be exercised in selection of patients, in administration of the drug and in continuous observation of patients receiving it.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERSHOF E., OXMAN A. C. Agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):557–558. doi: 10.1001/jama.1953.02940070023007b. [DOI] [PubMed] [Google Scholar]
- CHARET R., SIEGEL I. Unusual reaction following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):556–557. doi: 10.1001/jama.1953.02940070022007a. [DOI] [PubMed] [Google Scholar]
- GUTMAN A. B., YU T. F. Current principles of management in gout. Am J Med. 1952 Dec;13(6):744–759. doi: 10.1016/0002-9343(52)90374-4. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., BROWN B., MANKLE E. A. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952 Jun 21;149(8):729–734. doi: 10.1001/jama.1952.02930250011004. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W. Phenylbutazone (butazolidin) and butapyrin; a study of clinical effects in arthritis and gout. Calif Med. 1952 Nov;77(5):319–325. [PMC free article] [PubMed] [Google Scholar]
- PATTERSON R. M., BENSON J. F., SCHOENBERG P. L. Clinical evaluation of phenylbutazone. U S Armed Forces Med J. 1953 Jan;4(1):109–111. [PubMed] [Google Scholar]
- SMITH C. H., KUNZ H. G. Butazolidin in rheumatoid disorders; a preliminary report. J Med Soc N J. 1952 Jul;49(7):306–309. [PubMed] [Google Scholar]
- STEPHENS C. A. L., Jr, YEOMAN E. E., HOLBROOK W. P., HILL D. F., GOODIN W. L. Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis. J Am Med Assoc. 1952 Nov 15;150(11):1084–1086. doi: 10.1001/jama.1952.03680110024007. [DOI] [PubMed] [Google Scholar]
- STIFEL J. L., BURNHEIMER J. C. Agranulocytosis following administration of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):555–556. doi: 10.1001/jama.1953.02940070021007. [DOI] [PubMed] [Google Scholar]
- WERBLOW S. C., NEBER J. Agranulocytosis following phenylbutazone therapy. J Am Med Assoc. 1953 Apr 11;151(15):1286–1289. doi: 10.1001/jama.1953.02940150026006a. [DOI] [PubMed] [Google Scholar]
- WILKINSON E. L., BROWN H. The effect of butazolidin (phenylbutazone) on water and electrolyte excretion. Am J Med Sci. 1953 Feb;225(2):153–158. doi: 10.1097/00000441-195302000-00007. [DOI] [PubMed] [Google Scholar]